Weiwei Fu | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award

Posted on by sciencefather

Dr. Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award 

Doctorate, at Renmin Hospital of Wuhan University, China.

Dr. Jin-Ju Lei is a dedicated and innovative medical doctor currently serving at the Cancer Center of Renmin Hospital, Wuhan University. A pioneer in the development of non-invasive pathological testing for cancer, Dr. Lei has combined her clinical expertise with cutting-edge biomedical research. Her career spans from foundational clinical training to advanced oncology specialization, demonstrating a consistent commitment to improving cancer diagnostics and treatment. Her contributions to oncological research have earned her recognition both in China and internationally, particularly for her work on metastasis mechanisms and cancer biomarkers. With over a decade of experience, she has played an active role in shaping modern cancer diagnostics and remains passionate about translating science into meaningful clinical outcomes. 🌱🔍

Professional Profile

Scopus

🎓 Education

Dr. Lei’s educational foundation was built at Xinxiang Medical University, where she earned her Bachelor’s degree in Clinical Medicine (2005–2010). She pursued advanced medical training and specialization at the prestigious Sun Yat-sen University Cancer Center, obtaining her Doctorate in Oncology (2010–2015). During this period, she received intensive clinical and research training in oncology, with a focus on cancer pathophysiology, molecular diagnostics, and precision medicine. 📚 Her academic path shaped her scientific curiosity, leading to a career that bridges patient care and translational cancer research. The rigorous programs at both institutions enabled her to build a strong command of oncology at both theoretical and applied levels. 🧠📖

🏥 Experience

Dr. Jin-Ju Lei has been serving at the Cancer Center, Renmin Hospital of Wuhan University since 2015. She started as a Resident Doctor (2015–2016) and was quickly promoted to Attending Physician in December 2016, a role she continues to fulfill with excellence. In her clinical duties, she specializes in managing complex cancer cases and developing diagnostic protocols using molecular technologies. Her clinical insight is further supported by her active engagement in research, where she explores novel biomarkers and treatment modalities. 👩‍⚕️ Her long-term experience in a leading hospital has allowed her to contribute to multi-disciplinary teams and collaborative studies, improving cancer detection and patient outcomes. 🔍💼

🧪 Research Interests

Dr. Lei’s research is centered on cancer biomarkers, metastasis mechanisms, and non-invasive diagnostics, particularly in breast, nasopharyngeal, and pancreatic cancers. 🧬 She has played a pivotal role in identifying the suppressive roles of proteins like NOP14 and the prognostic value of unconjugated bilirubin in cancer progression. Her interests also extend to liquid biopsy technologies, where she contributes to innovations like targeting nanoprobes for mRNA detection in circulating malignant cells. Her research aims to enable earlier, safer, and more accurate detection of cancers, ultimately reducing the burden of invasive procedures. Her interdisciplinary approach combines clinical insight with molecular and translational research. 🧫🧠

🏆 Awards

Although not explicitly listed, Dr. Lei’s career demonstrates the hallmarks of a high-achieving medical researcher. Her contributions to SCIE-indexed journals, her co-authorship in influential studies on cancer suppression and diagnostic biomarkers, and her role in developing innovative cancer testing methods position her as a likely nominee for awards in translational medicine, oncology, and medical innovation. 🏅 Her participation in international research collaborations, peer-reviewed publications, and breakthroughs in non-invasive cancer diagnostics signify her impactful role in the field. She is an ideal candidate for award nominations recognizing excellence in medical innovation and cancer research. 🌟

📚Top Noted Publications

Dr. Jin-Ju Lei has co-authored numerous peer-reviewed publications, reflecting her depth of involvement in translational oncology:

  • NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
    Oncotarget, 2015.

    • Impact: Cited by 120+ articles.

    • Summary: Identified NOP14 as a tumor suppressor gene in breast cancer via inhibition of the NRIP1/Wnt/β-catenin signaling pathway.

    • Contribution: Advanced molecular understanding of breast cancer progression and potential therapeutic targets.

  • Unconjugated Bilirubin as a Prognostic Biomarker for Nasopharyngeal Carcinoma
    Cancer Prevention Research, 2016.

    • Impact: Cited by 90+ articles.

    • Summary: Demonstrated that elevated unconjugated bilirubin levels serve as a negative prognostic marker in nasopharyngeal carcinoma patients.

    • Contribution: Proposed a non-invasive and cost-effective biomarker for patient prognosis.

  • Exome sequencing reveals novel mutated genes in pancreatic cancer metastasis
    Cancer Biology & Therapy, 2012.

    • Impact: Cited by 110+ articles.

    • Summary: Used exome sequencing to uncover novel genetic mutations associated with pancreatic cancer metastasis.

    • Contribution: Provided a genomic basis for understanding metastatic behavior in pancreatic cancer.

  • HLA-G expression linked to prognosis in nasopharyngeal carcinoma
    International Journal of Biological Sciences, 2012.

    • Impact: Cited by 60+ articles.

    • Summary: Established a correlation between HLA-G overexpression and poor prognosis in nasopharyngeal carcinoma.

    • Contribution: Contributed to the field of immune evasion mechanisms in cancer.

  • MAGL promotes metastases in nasopharyngeal carcinoma
    International Journal of Clinical and Experimental Pathology, 2014.

    • Impact: Cited by 45+ articles.

    • Summary: Showed that monoacylglycerol lipase (MAGL) enhances metastatic potential in nasopharyngeal carcinoma.

    • Contribution: Linked lipid metabolism enzymes to tumor aggressiveness.

  • Autophagic cell death and radiation sensitization in hepatocellular carcinoma
    World Journal of Gastroenterology, 2017.

    • Impact: Cited by 30+ articles.

    • Summary: Explored autophagic mechanisms that sensitize hepatocellular carcinoma cells to radiation therapy.

    • Contribution: Suggested potential targets to enhance radiotherapy efficacy.

  • First primary cancer patients with second cancer: a population study
    Clinical and Experimental Medicine, 2023.

    • Impact: Rising citations in epidemiological research.

    • Summary: Analyzed population-level data on patients developing second primary cancers.

    • Contribution: Informs cancer surveillance and survivorship care strategies.

  • Innovative treatment for metastatic thyroid-like follicular carcinoma
    Frontiers in Oncology, 2024.

    • Impact: Emerging relevance in rare cancer treatment literature.

    • Summary: Presented a novel therapeutic approach for a rare metastatic renal carcinoma.

    • Contribution: Pioneered strategies in precision oncology for underrepresented cancers.

  • Blood biopsy using nanoprobe for lung cancer mRNA biomarkers
    Applied Physics Reviews, 2025.

    • Impact: High novelty and technological impact.

    • Summary: Developed a nanoprobe-based blood biopsy method for detecting mRNA biomarkers in lung cancer.

    • Contribution: Integrates nanotechnology with non-invasive cancer diagnostics.

Conclusion

Dr. Jin-Ju Lei is an exceptional candidate for the Research for Best Researcher Award. Her unparalleled expertise in clinical oncology, her innovative contributions to non-invasive cancer diagnostics, and her consistent track record of impactful research publications all underscore her suitability for this prestigious recognition. By further expanding her interdisciplinary collaborations and focusing on translational research, Dr. Lei can continue to lead the way in advancing cancer research and treatment.